Autolus Therapeutics Appoints New Director

Ticker: AUTL · Form: 8-K · Filed: 2025-05-30T00:00:00.000Z

Sentiment: neutral

Topics: board-change, governance

TL;DR

Autolus adds a new director to the board.

AI Summary

Autolus Therapeutics plc announced on May 23, 2025, a change in its board of directors. Dr. Christian Höbat has been appointed as a new director. The company also reported on compensatory arrangements for its officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — The filing primarily concerns board appointments and compensatory arrangements, which are routine corporate governance events.

Key Players & Entities

FAQ

Who has been appointed as a new director to the board of Autolus Therapeutics plc?

Dr. Christian Höbat has been appointed as a new director.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 23, 2025.

What type of company is Autolus Therapeutics plc?

Autolus Therapeutics plc is a company in the Biological Products sector, specifically SIC code 2836.

What is the primary jurisdiction of incorporation for Autolus Therapeutics plc?

Autolus Therapeutics plc is incorporated in England and Wales.

What other items are covered in this 8-K filing besides director changes?

The filing also covers the election of directors and compensatory arrangements of certain officers.

From the Filing

0001193125-25-132111.txt : 20250530 0001193125-25-132111.hdr.sgml : 20250530 20250530160600 ACCESSION NUMBER: 0001193125-25-132111 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250523 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250530 DATE AS OF CHANGE: 20250530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 251010856 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 d908343d8k.htm 8-K 8-K 00-0000000 0001730463 false true 0001730463 2025-05-23 2025-05-23 0001730463 sic:Z8880 2025-05-23 2025-05-23 0001730463 us-gaap:CommonClassAMember 2025-05-23 2025-05-23     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025     Autolus Therapeutics plc (Exact name of registrant as specified in its Charter)       England and Wales   001-38547   Not applicable (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) ( 44 ) 20 3829 6230 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share   AUTL   The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share*   *   The Nasdaq Stock Market LLC *   * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rul

View on Read The Filing